Drug Profile
AGY 203
Latest Information Update: 10 Oct 2006
Price :
$50
*
At a glance
- Originator AGY Therapeutics
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 24 Apr 2002 Preclinical trials in Stroke in USA (unspecified route)